Date/Time |
05/26 / 16:01 |
Chg. / Chg.(%) |
2.1700 / +1.07% |
Bid |
204.0600 / 100 |
Ask |
204.5300 / 100 |
Open |
202.9800 |
Previous Close |
202.3600 |
High |
204.5500 |
Low |
202.3400 |
Volume [USD] |
3,717,655.5350 |
Volume [Units] |
39,912 |
Price fixings |
101 |
ISIN |
US09062X1037 |
Security |
BIIB |
Exchange |
NASDAQ |
Type |
Stock |
- Biogen revenue slips 6% to $2.53B in Q1
05/03/2022 / 13:09 - TeleTrader
-
- BIIB 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
03/29/2022 / 15:36 - GlobeNewswire
-
- Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
03/28/2022 / 13:30 - GlobeNewswire
-
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm
03/28/2022 / 03:00 - GlobeNewswire
-
- Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
03/22/2022 / 12:00 - GlobeNewswire